Mark Ligorski, MD
Psychiatry · Norwalk, CTNPI 1659465003
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,672 of the $7,711 with a category attached, or 73.6%. 22 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 29.5% of the total. Reporting peaked in 2024 at $2,935 and has fallen 65.6% since, to $1,009 in 2025. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $31.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$2K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$507
- Neurocrine Biosciences, Inc.$432
- Otsuka America Pharmaceutical, Inc.$429
- plus $2K from 16 others
What the payments were for
- Consulting fees$2,00026%
- Travel & lodging$401%
- Food & beverage$5,67274%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 11 | $2,272 |
| AbbVie(2 entities) | 56 | $1,283 |
| Teva Pharmaceuticals USA, Inc. | 38 | $1,009 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $507 |
| Neurocrine Biosciences, Inc. | 16 | $432 |
| Otsuka America Pharmaceutical, Inc. | 18 | $429 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $301 |
| Corium, LLC | 13 | $279 |
| Avanir Pharmaceuticals, Inc. | 11 | $269 |
| Vanda Pharmaceuticals Inc. | 13 | $246 |
| Alkermes, Inc. | 5 | $107 |
| Lundbeck LLC | 5 | $106 |
| Sunovion Pharmaceuticals Inc. | 5 | $97 |
| Johnson & Johnson | 4 | $88 |
| Tris Pharma Inc | 4 | $75 |
| Arbor Pharmaceuticals, Inc. | 2 | $45 |
| Bausch Health US, LLC | 2 | $35 |
| Almatica Pharma LLC | 2 | $33 |
| Neos Therapeutics, LP | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Harmony Biosciences LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,711 in reported general payments places this provider in the 90th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 18 | $137,539 |
| RexultiBrexpiprazole | 25 | $50,610 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $23,134 |
| TrintellixVortioxetine Hydrobromide | 27 | $19,311 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $7,000 |
| FetzimaLevomilnacipran Hcl | 12 | $6,203 |
| BelsomraSuvorexant | 12 | $5,367 |
| ConcertaMethylphenidate Hcl | 11 | $4,270 |
| Divalproex Sodium ErDivalproex Sodium | 28 | $3,370 |
| Vilazodone Hcl | 11 | $3,324 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 97 | $3,042 |
| Duloxetine Hcl | 125 | $2,875 |
| Bupropion XlBupropion Hcl | 147 | $2,768 |
| Quetiapine Fumarate | 111 | $2,766 |
| Lorazepam | 198 | $2,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $432 | $137,53918 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $429 | $50,61025 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $507 | $26,31139 claims |
| Axsome Therapeutics, Inc.Auvelity | $2,272 | $23,13418 claims |
| AbbVieFetzima | $1,283 | $6,20312 claims |
| Johnson & JohnsonConcerta | $88 | $4,27011 claims |
| Almatica Pharma LLCSertraline Hcl | $33 | $98397 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Norwalk
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
- John KrystalWest Haven$122K
- David MatuskeyFarmington$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.